News

Sun Pharmaceutical Industries Ltd share price gained 0.87% to Rs 1778.25 after the company`s net profit plunged by 31.24% to Rs 2001.58 crore, while revenue from operations slightly gained 6.04% to Rs 16100.01 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.48%. It has marginally improved by 6.57% over last one week and ticked higher by 1.39% in last one month while the market capitalization of Sun Pharmaceutical Industries Ltd has inched up 2.02% and 10.61% in the same period respectively. Profit before tax (PBT) of Sun Pharmaceutical Industries Ltd stood at Rs 3159.37 crore in Q3 FY26, tumbling by 24.19% year-on-year, and plunging by 22.92% quarter-on-quarter. EBITDA came in at Rs 4227 crore, rising 4.18% YoY and heading higher 14.42% sequentially. Total expenses saw a slight increase of 5.10% to Rs 12213.16 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 2318.7 crore, going up by 14.43% YoY, while employee benefits expense was at Rs 3274.16 crore, ticking higher by 1.45% YoY. For the TTM ended FY26, revenue from operations advanced 11.87% to Rs 58220.11 crore, while net profit grew slightly 5.32% to Rs 11564.52 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1366811% to Rs 15759.68 crore, and PBT saw a minor gain of 9.94% to Rs 15118.88 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 12419.18 crore in FY26, as against Rs 14072.09 crore in FY25. Sun Pharmaceutical Industries Ltd ticked higher by 4.38% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 11.78% during the same period.

Sun Pharmaceutical Industries Ltd share price ticked higher by 0.28% to Rs 1762.95 after the company`s net profit tumbled by 31.24% to Rs 2001.58 crore, while revenue from operations improved marginally 6.04% to Rs 16100.01 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.62%. It has improved by 5.74% over last one week and gained upto 0.60% in last one month while the market capitalization of Sun Pharmaceutical Industries Ltd has inched up 1.14% and 11.38% in the same period respectively. Profit before tax (PBT) of Sun Pharmaceutical Industries Ltd stood at Rs 3159.37 crore in Q3 FY26, crashing by 24.19% year-on-year, and plunging by 22.92% quarter-on-quarter. EBITDA came in at Rs 4227 crore, gaining 4.18% YoY and advancing by 14.42% sequentially. Total expenses saw a slight increase of 5.10% to Rs 12213.16 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 2318.7 crore, going up by 14.43% YoY, while employee benefits expense was at Rs 3274.16 crore, easing 1.45% YoY. For the TTM ended FY26, revenue from operations rose 11.87% to Rs 58220.11 crore, while net profit saw a marginal increase of 5.32% to Rs 11564.52 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1366811% to Rs 15759.68 crore, and PBT saw a minor gain of 9.94% to Rs 15118.88 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 12419.18 crore in FY26, as against Rs 14072.09 crore in FY25. Sun Pharmaceutical Industries Ltd ticked higher by 2.71% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.

Sun Pharmaceutical Industries Limited completed the private placement allotment of Rs 7,816 crore in rated, listed, unsecured, redeemable, non-convertible debentures (NCDs) on October 26, 2026, exceeding the base issue size of Rs 7,000 crore by exercising a greenshoe option of Rs 816 crore. The NCDs consist of Series A debentures with an aggregate face value of Rs 2,003 crore and Series B debentures with an aggregate face value of Rs 5,813 crore, and will be listed on the National Stock Exchange of India Limited and BSE Limited, with a scheduled redemption date of October 27, 2031.

Sun Pharmaceutical Industries Limited submitted a confirmation certificate dated October 3, 2026, received from MUFG Intime India Private Limited, its Registrar & Share Transfer Agent, pertaining to the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Sun Pharmaceutical Industries Limited will close its trading window for share transactions starting October 1, 2026, and continuing until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, according to a filing with the National Stock Exchange of India Limited and BSE Limited.